- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada - - Patient recruitment for ReSTART U.S. multi-center pivotal trial and for pancreatic cancer feasibility and safety studies in Canada and Israel currently ongoing - - Cash, cash equivalents, deposits & restricted deposits ...

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that its first patient with liver cancer metastases has been treated in a feasibility and safety study of Alpha DaRT at the McGill University Health Center in Montreal, Canada. The trial seeks to recruit up to 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of ...

- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both Panc02 and KPC tumor models - JERUSALEM, May 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the presentation of new preclinical data at the 2024 congress of th ...

- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits balance of $84.9 million, with anticipated runway for at least two years - JERUSALEM, March 07, 2024 (GLOB ...

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update - Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - Exhibit 99.1 - Submitted PMDA application for recurrent Head and Neck cancer in Japan - - Entered into long-term lease for a second facility in the U.S. in Hudson, NH - - Cash, deposits and restricted deposits ba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ OR ☐ SHELL COMPANY REPORT PURSUANT TO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 O ...

Exhibit 99.1 Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update - Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - -Pursued supply chain expansion in Israel, the U.S. and Japan, including increases in radioactive license capacities - - Cash & equivalents balance of $105.4 million, with runway for at least two years - Balan ...

Exhibit 99.1 Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update -Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds- -100% complete response (CR) observed in U.S. multi-center pilot trial of skin cancers at 12 weeks- -Targeted start of U.S. multi-center pivotal trial in skin cancers by the middle of 2022- JERUSALEM, March 28, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUA ...